Based on this hypothesis, we propose that the TDO–Kyn–AhR pathway can be characterized in blood samples from patients with acute HCV infections, persistent HCV infections and no HCC, persistent HCV-associated HCC and healthy controls. This evidence concerns the gene AHR and hepatocellular carcinoma.